RxDoctor Payments Data

Anthony Lutz

Adult Health · Summit, NJNPI 1407272982

Payments from drug & device makers

$1,223in general payments, 2019–2025

Across 32 payments — averaging $38.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • C. R. Bard, Inc. & Subsidiaries$270
  • Boston Scientific$220
  • Sumitomo Pharma America, Inc.$191
  • Johnson & Johnson$108
  • Astellas Pharma US Inc$76
  • Urovant Sciences Inc$72
  • plus $286 from 8 others

What the payments were for

  • Consulting fees$27022%
  • Food & beverage$85069%
  • Education$1038%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,223 in reported general payments places this provider in the 70th percentile of 1,135 adult health providers in New Jersey.

See all adult health providers in New Jersey

Medicare billing

Part B allowed, 2024
$46,161
Medicare patients
205
Services billed
1,259

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron33$21,868
GemtesaVibegron21$18,853
Tamsulosin Hcl218$3,440
Methenamine Hippurate13$1,658
Silodosin16$1,330
Finasteride92$1,027
Alfuzosin Hcl ErAlfuzosin Hcl26$606
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip14$319
Solifenacin Succinate11$287
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst14$148
Doxycycline Hyclate12$107
Oxybutynin Chloride ErOxybutynin Chloride11$92
Ciprofloxacin Hcl20$89
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim24$78
Cephalexin17$56

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$76$21,86833 claims
Sumitomo Pharma America, Inc.Gemtesa$191$18,85321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,135 adult health providers in New Jersey.

Other adult health in Summit

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →